Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

Aug 01 2011

• By Daniel Chancellor

Listen to this article

While Merck’s latest job cuts were at the fore of its Q2 update (scripintelligence.com, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.

While Merck’s latest job cuts were at the fore of its Q2 update (scripintelligence.com, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.

Merck’s decision to discontinue telcagepant was based on an assessment of data across the clinical program, including findings from a...

More from Neurological

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1
Dec 10 2024
• By Saba Afreen
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.